Výsledky vyhledávání - "F J Hernandez-Ilizaliturri"

Akademický článek

P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)

Autor: F. J. Hernandez-Ilizaliturri, J. Kuruvilla, B. A. Christian, I. W. Flinn, S. E. Assouline, M. L. Ulrickson, D. J. Landsburg, M. Stuart, H. Lowman, N. Levin, D. Maetzel, N. N. Viller, A. MacLaren

Publikováno v: HemaSphere, Vol 6, Pp 1039-1040 (2022)

Externí odkaz: https://doaj.org/article/da6d30c2b49f4c2c96a820d37727e01c

Zobrazit plný text záznamu

Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib

Autor: I Maraj, F J Hernandez-Ilizaliturri, M Chisti, M S Czuczman

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5738687ff92106943d45ba091fa29ac1

Zobrazit plný text záznamu

Structural changes in the internal domain of the CD20 antigen is associated with the development of rituximab resistance: Effects on signaling and redistribution of CD20 into lipid raft domains in rituximab-resistant cell lines (RRCL)

Autor: A. C. Gowda, F. J. Hernandez-Ilizaliturri, G. Connolly, M. S. Czuczman

Publikováno v: Journal of Clinical Oncology. 22:2502-2502

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2927c03c4d38a240d26dc3b4bb7bb946
https://doi.org/10.1200/jco.2004.22.90140.2502

Zobrazit plný text záznamu